EFPIA joining the fight against coronavirus

4 February 2020

Trade group the European Federation of Pharmaceutical Industries and Associations (EFPIA) is now joining the fight against the outbreak of coronavirus in China, rallying its member companies to come forward with potential treatment.

In a web posting it says: “At EFPIA our first thoughts are with all those affected by the recent outbreak of the coronavirus (nCov-2019). Considering the public health and humanitarian implications, we are committed to joining global efforts to care for those affected, contain the outbreak and develop resources to tackle future outbreaks.

“To that end, we have issued a call to EFPIA members to identify suitable assets in their libraries that could be utilized in the fight against coronaviruses.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK